REVONTO dantrolene sodium for injection 20 mg/vial (USA)

Dantrolene is indicated, along with appropriate supportive measures, for the management of the fulminant hypermetabolism of skeletal muscle characteristic of malignant hyperthermia (MH) crisis. It should be administered by intravenous injection as soon as the MH reaction is recognised (i.e., tachycardia, tachypnea, central venous desaturation, hypercarbia, metabolic acidosis, skeletal muscle rigidity, increased utilisation of anaesthesia circuit carbon dioxide absorber, cyanosis and mottling of the skin, and, in many cases, fever).